Cyclodextrins in peptide and protein delivery

Advanced Drug Delivery Reviews

Volumn 36, Issue 1, 1999, Pages 101-123

  Irie, Tetsumi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Absorption enhancers; Artificial chaperones; Cyclodextrins; Heparinoids; Inclusion complex; Oligonucleotides; Peptides and proteins; Solubilizing and stabilizing agents; Sustained release carriers

Indexed keywords

AMINO ACIDS; COMPLEXATION; CONTROLLED DRUG DELIVERY; DERIVATIVES; DRUG DOSAGE; POLYPEPTIDES; PROTEINS;

CYCLODEXTRINS; DRUG CARRIERS; INCLUSION COMPLEXES;

POLYSACCHARIDES;

BASIC FIBROBLAST GROWTH FACTOR; BUSERELIN; CHYMOTRYPSIN A; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN A; GROWTH HORMONE; HEPARINOID; INSULIN; PROTEIN;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; HEMOLYSIS; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY;

EID: 0033105151     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00057-X     Document Type: Review

References (151)

1. R. Pearlman, Y.J. Wang (Eds.), Formulation, characterization, and stability of protein drugs. Plenum Press, New York and London, 1996.
2. A.P. Sayani, Y.W. Chien, Systemic delivery of peptides and proteins across absorptive mucosae, CRC Crit. Rev. Ther. Drug Carrier Syst. 13 (1996) 85-184.
3. K. Uekama, F. Hirayama, T. Irie, Cyclodextrin drug carrier systems, Chem. Rev. 98 (1998) 2045-2076.
4. D.O. Thompson, Cyclodextrins-Enabling excipients: Their present and future use in pharmaceuticals, CRC Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 1-104.
5. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. III. Toxicological issues ans safety evaluation, J. Pharm. Sci. 86 (1997) 147-162.
6. T. Irie, M. Otagiri, M. Sunada, et al., Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro, J. Pharmacobio.-Dyn. 5 (1982) 741-744.
7. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga, J. Pitha, Differential effects of α-, β-and γ-cyclodextrins on human erythrocytes, Eur. J. Biochem. 186 (1989) 17-22.
8. I. Miyazaki, H. Ueda, H. Nagase, T. Endo, S. Kobayashi, T. Nagai, Physicochemical properties and inclusion complex formation of 5-cyclodextrin, Eur. J. Pharm. Sci. 3 (1995) 153-162.
9. K. Miyajima, H. Saito, M. Nakagaki, Destruction of liposome by cyclodextrins, J. Pharmacobio.-Dyn. 10 (1987) s123.
10. A. Yoshida, H. Arima, K. Uekama, J. Pitha, Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins, Int. J. Pharm. 46 (1988) 217-222.
11. Y. Okada, Y. Kubota, K. Koizumi, S. Hizukuri, T. Ohfuji, K. Ogata, Some properties and the inclusion behavior of branched cyclodextrins, Chem. Pharm. Bull. 36 (1988) 2176-2185.
12. A. Yoshida, M. Yamamoto, T. Irie, F. Hirayama, K. Uekama, Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-β-cyclodextrins and their solubilizing and stabilizing abilities, Chem. Pharm. Bull. 37 (1989) 1059-1063.
13. H. Suzuki, H. Ueda, S. Kobayashi, T. Nagai, Panosyl-β-cyclodextrin and its solubilization ability for poorly water soluble drugs, Eur. J. Pharm. Sci. 1 (1993) 159-164.
14. F. Attioui, A. al-Omar, E. Leray, H. Parrot-Lopez, C. Finance, R. Bonaly, Recognition ability and cytotoxicity of some oligosaccharidyl substituted β-cyclodextrins, Biol. Cell 82 (1994) 161-167.
15. E.J. Macarak, K. Kumor, P.B. Weisz, Sulfation and hemolytic activity of cyclodextrin, Biochem. Pharmacol. 42 (1991) 1502-1503.
16. P.B. Weisz, K. Kumor, E.J. Macarak, Protection of erythrocytes against hemolytic agents by cyclodextrin polysulfate, Biochem. Pharmacol. 45 (1993) 1011-1016.
17. K. Shiotani, K. Uehata, T. Irie, K. Uekama, D.O. Thompson, V.J. Stella, Differential effects of sulfate and sulfobutyl ether of β-cyclodextrin on erythrocyte membranes in vitro, Pharm. Res. 12 (1995) 78-84.
18. J. Pitha, Cyclodextrin derivatives with enhanced solubilizing power and lower toxicity. in: J.L.V. Jato, J.J.T. Labandeira (eds.), Proc. 9th Int. Symp. Cyclodextrins, Imprenta Roma, Santiago de Compostela, 1998, in press.
19. S. Mieda, F. Hirayama, K. Uekama, Preparation and pharmaceutical evaluation of heptakis(2,6-di-O-methyl-3-O-acetyl)-β-cyclodextrin, in: J.L.V. Jato. Labandeira (Eds.), Proc. 9th Int. Symp. Cyclodextrins, Imprenta Roma, Santiago de Compostela, 1998, in press.
20. J. Pitha, T. Irie, P.B. Sklar, J.S. Nye, Drug solubilizers to aid pharmacologists: Amorphous cyclodextrin derivatives, Life Sci. 43 (1988) 493-502.
21. R.P. Garay, J.C. Féray, K. Fanous, C. Nazaret, M.J. Villegas, J.F. Letavernier, A new approach for the in vitro evaluation of cyclodextrin effects on cellular membranes of human cells, in: T. Osa, et al. (Eds.), Proc. 7th Int. Cyclodextrins Symp., Komiyama, Tokyo, 1994, pp 373-376.
22. L. Hovgaard, H. Brøndsted, Drug delivery studies in Caco-2 monolayers. IV Absorption enhancer effects of cyclodextrins, Pharm. Res. 12 (1995) 1328-1332.
23. K. Nakanishi, T. Masukawa, K. Miyajima, The interaction with cyclodextrin and biological membrane on the drug absorption, in: Osa, T. et al. (Eds.), Proc. 7th Int. Cyclodextrins Symp., Komiyama, Tokyo, 1994, pp. 377-381.
24. F. Leroy-Lechat, D. Wouessidjewe, J.-P. Andreux, F. Puisieux, D. Duchêne, Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives, Int. J. Pharm. 101 (1994) 97-103.
25. R. Bar, S. Ulitzur, Bacterial toxicity of cyclodextrins: Luminuous Escherichia coli as a model, Appl. Microbiol. Biotechnol. 41 (1994) 574-577.
26. M. Maletic, H. Wennemers, D.Q. McDonald, R. Breslow, W.C. Still, Selective binding of the dipeptides L-Phe-D-Pro and D-Phe-L-Pro to β-cyclodextrin, Angew. Chem. Int. Ed. Engl. 35 (1996) 1490-1492.
27. Y. Liu, Y.-M. Zhang, A.D. Qi, R.-T. Chen, K. Yamamoto, T. Wada, Y. Inoue, Molecular recognition study on a supramolecular system. 10. Inclusion complexation of modified β-cyclodextrins with amino acids: enhanced enantioselectivity for L/D-leucine, J. Org. Chem. 62 (1997) 1826-1830.
28. A. Cooper, Effect of cyclodextrins on the thermal stability of globular proteins, J. Am. Chem. Soc. 114 (1992) 9208-9209.
29. J. Horsky, J. Pitha, Inclusion complexes of proteins: Interaction of cyclodextrins with peptides containing aromatic amino acids studied by competitive spectrophotometry, J. Inclu. Phenom. Mol. Recognit. Chem. 18 (1994) 291-300.
30. R. Breslow, Z. Yang, R. Ching, G. Trojandt, F. Odobel, Sequence selective binding of peptides by artificial receptors in aqueous solution, J. Am. Chem. Soc. 120 (1998) 3536-3537.
31. K. Matsubara, T. Irie, K. Uekama, Spectroscopic characterization of the inclusion complex of a luteinizing hormone-releasing hormone agonist, buserelin acetate, with dimethyl-β-cyclodextrin, Chem. Pharm. Bull. 45 (1997) 378-383.
32. S. Tajiri, T. Tahara, K. Tokihiro, T. Irie, K. Uekama, Effects of hydrophilic cyclodextrins on tertiary structures of protein drugs, in A. Ueno (Ed.), Proc. 15th Cyclodextrin Symp., Tokyo, 1997, pp 35-36.
33. B. Mikami, E.J. Hehre, M. Sato, Y. Katsube, M. Hirose, Y. Morita, J.C. Sacchettini, The 2.0-Å resolution structure of soybean β-amylase complexed with α-cyclodextrin, Biochemistry 32 (1993) 6836-6845.
34. A.J. Sharff, L.E. Rodseth, F.A. Quiocho, Refined 1.8-Å structure reveals the mode of binding of β-cyclodextrin to the maltodextrin binding protein, Biochemistry 32 (1993) 10553-10559.
35. J.A. Hall, T.E. Thorgeirsson, J. Liu, Y.-K. Shin, H. Nikaido, Two modes of ligand binding in maltose-binding protein of Escherichia coli, J. Biol. Chem. 272 (1997) 17610-17614.
36. M.P. Williamson, M.-F. Le Gal-Coëffet, K. Sorimachi, C.S.M. Furniss, D.B. Archer, G. Williamson, Function of conserved tryptophans in the Aspergillus niger glucoamylase 1 starch binding domain, Biochemistry 36 (1997) 7535-7539.
37. K. Sorimachi, M.-F. Le Gal-Coëffet, G. Williamson, D.B. Archer, M.P. Williamson, Solution structure of the granular starch binding domain of Aspergillus niger glucoamylase bound to β-cyclodextrin, Structure 5 (1997) 647-661.
38. M.E. Brewster, M.S. Hora, J.W. Simpkins, N. Bodor, Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs, Pharm. Res. 8 (1991) 792-795.
39. S.A. Charman, K.L. Mason, W.N. Charman, Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone, Pharm. Res. 10 (1993) 954-962.
40. 2a monoclonal antibody (MN12), Pharm. Res. 9 (1992) 266-270.
41. R.J. Prankerd, H.W. Stone, K.B. Sloan, J.H. Perrin, Degradation of aspartame in acidic aqueous media and its stabilization by complexation with cyclodextrins or modified cyclodextrins, Int. J. Pharm. 88 (1992) 189-199.
42. M.S. Hora, R.K. Rana, F.W. Smith, Lyophilized formulations of recombinant tumor necrosis factor, Pharm. Res. 9 (1992) 33-36.
43. M. Katakam, A.K. Banga, Aggregation of proteins and its prevention by carbohydrate excipients: Albumins and γ-globulin, J. Pharm. Pharmacol. 47 (1995) 103-107.
44. K. Izutsu, S. Yoshioka, S. Kojima, Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices, Pharm. Res. 12 (1995) 838-843.
45. A. Kanai, R.M. Alba, T. Takano, et al., The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops, Transplantation Proc. 21 (1989) 3150-3152.
46. T. Ichikawa, A. Kanai, Y. Yamazaki, Tear secretion-stimulating effect of cyclosporin A eyedrops in rabbits, Atarashii Ganka (Journal of the Eye) 12 (1995) 983-987.
47. H. Hatanaka, F. Komada, S. Iwakawa, C. Yamagami, K. Okumura, Effect of dimethyl-α-cyclodextrin on the gastrointestinal absorption of cyclosporin, Jpn. J. Hosp. Pharm. 21 (1995) 295-301.
48. K. Miyake, T. Irie, F. Hirayama, K. Uekama, Improvements of gastrointestinal absorption and lymphatic transfer of cyclosporin A by various cyclodextrins, Drug Deliv. Syst. 13 (1998) 369-375.
49. K. Miyake, T. Irie, F. Hirayama, K. Uekama, Improved solubility and oral bioavailability of cyclosporin A by hydrophilic cyclodextrin complexation. in: J.L.V. Jato, J.J.. Labandeira (Eds.), Proc. 9th Int. Symp. Cyclodextrins, Imprenta Roma, Santiago de Compostela, 1998, in press.
50. Brange, J., Stability of Insulin, Kluwer Academic, Boston, 1994.
51. K. Tokihiro, T. Irie, K. Uekama, J. Pitha, Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution, Pharm. Sci. 1 (1995) 49-53.
52. A.K. Banga, R. Mitra, Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins, J. Drug Targeting 1 (1993) 341-345.
53. M. Katakam, A.K. Banga, Aggregation of insulin and its prevention by carbohydrate excipients, PDA J. Pharm. Sci. Tech. 49 (1995) 160-165.
54. K. Tokihiro, T. Irie, F. Hirayama, K. Uekama, Mass spectroscopic evidence on inhibiting effect of maltosyl-β-cyclodextrin on insulin self-association, Pharm. Sci. 2 (1996) 519-522.
55. M. Lovatt, A. Cooper, P. Camilleri, Energetics of cyclodextrin-induced dissociation of insulin, Eur. Biophys. J. 24 (1996) 354-357.
56. K. Tokihiro, T. Irie, K. Uekama, Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution, Chem. Pharm. Bull. 45 (1997) 525-531.
57. K. Tokihiro, T. Irie, K. Uekama, Differential effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin, in: J. Szejtli, L. Szente (Eds.), Proc. 8th Int. Symp. Cyclodextrins, Kluwer Academic, the Netherlands, 1996, pp. 357-360.
58. P. Camilleri, N.J. Haskins, D.R. Howlett, β-Cyclodextrin interacts with the Alzheimer amyloid β-A4 peptide, FEBS Lett. 341 (1994) 256-258.
59. J. Waite, G.M. Cole, S.A. Frautschy, D.J. Connor, L.J. Thal, Solvent effects on beta protein toxicity in vivo, Neurobiol. Aging 13 (1992) 595-599.
60. N. Karuppiah, A. Sharma, Cyclodextrins as protein folding aids, Biochem. Biophys. Res. Commun. 211 (1995) 60-66.
61. A. Cooper, M. Lovatt, M.A. Nutley, Energetics of protein-cyclodextrin interactions, J. Inclu. Phenom. Mol. Rec. Chem. 25 (1996) 85-88.
62. S. Tajiri, T. Tahara, K. Tokihiro, T. Irie, K. Uekama, Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone, in: J.L.V. Jato, J.J.T. Labandeira (Eds.), Proc. 9th Int. Symp. Cyclodextrins, Imprenta Roma, Santiago de Compostela, 1998, in press.
63. D. Rozema, S.H. Gellman, Artificial chaperones: Protein refolding via sequential use of detergent and cyclodextrin, J. Am. Chem. Soc. 117 (1995) 2373-2374.
64. D. Rozema, S.H. Gellman, Artificial chaperone-assisted refolding of carbonic anhydrase B, J. Biol. Chem. 271 (1996) 3478-3487.
65. D. Rozema, S.H. Gellman, Artificial chaperone-assisted refolding of denatured-reduced lysozyme: Modulation of the competition between renaturation and aggregation, Biochemistry 35 (1996) 15760-15771.
66. F. Couthon, E. Clottes, C. Vial, Refolding of SDS- and thermally denatured MM-creatine kinase using cyclodextrins, Biochem. Biophys. Res. Commun. 227 (1996) 854-860.
67. T. Shimamoto, Pharmaceutical aspects: Nasal and depot formulations of leuprolide, J. Androl. 8 (1987) S14-S16.
68. K. Matsubara, K. Abe, T. Irie, K. Uekama, Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats, J. Pharm, Sci. 84 (1995) 1295-1300.
69. F.W.H.M. Merkus, J.C. Verhoef, S.G. Romeijn, N.G.M. Schipper, Absorption enhancing effect of cyclodextrins on intranasally administered insulin in rats, Pharm. Res. 8 (1991) 588-592.
70. Z. Shao, R. Krishnamoorthy, A.K. Mitra, Cyclodextrins as nasal absorption promoters of insulin: Mechanistic evaluations, Pharm. Res. 9 (1992) 1157-1163.
71. T. Irie, K. Wakamatsu, H. Arima, H. Aritomi, K. Uekama, Enhancing effects of cyclodextrins on nasal absorption of insulin in rats, Int. J. Pharm. 84 (1992) 129-139.
72. Y. Watanabe, Y. Matsumoto, K. Kawamoto, S. Yazawa, M. Matsumoto, Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits, Chem. Pharm. Bull. 40 (1992) 3100-3104.
73. N.G.M. Schipper, J.C. Verhoef, L.M. De Lannoy, et al., Nasal administration of an ACTH(4-9) peptide analogue with dimethyl-β-cyclodextrin as an absorption enhancer: Pharmacokinetics and dynamics, Br. J. Pharmacol. 110 (1993) 1335-1340.
74. N.G.M. Schipper, J.C. Verhoef, S.G. Romeijn, F.W.H.M. Merkus, Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin, Calcif. Tissue Int. 56 (1995) 280-282.
75. Y. Watanabe, Y. Matsumoto, R. Kikuchi, et al., Pharmacokinetics and pharmacodynamics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) following intranasal administration in rabbits, J. Drug Targeting 3 (1995) 231-238.
76. K. Ukai, Y. Murakawa, Y. Kurosaki, T. Nakayama, T. Kimura, Nasal absorption of recombinant human insulin-like growth factor-I, Yakuzaigaku 56 (1996) 156-162.
77. W.J. Irwin, A.K. Dwivedi, P.A. Holbrook, M.J. Dey, The effect of cyclodextrins on the stability of peptides in nasal enzyme systems, Pharm. Res. 11 (1994) 1698-1703.
78. I.K. Chun, Y.W. Chien, Stabilization of methionine enkephalin in various rabbit mucosal extracts by enzyme inhibitors, Int. J. Pharm. 121 (1995) 217-231.
79. S.P. Kumble, C.S. Ramadoss, α-Chymotrypsin catalyzed hydrolysis of N-benzoyl-L-tyrosine ethyl ester anchored in β-cyclodextrin, Biocatalysis Biotransformation 12 (1995) 281-291.
80. K. Matsubara, Y. Ando, T. Irie, K. Uekama, Protection afforded by maltosyl-β-cyclodextrin against α-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate, Pharm. Res. 14 (1997) 1401-1405.
81. E. Marttin, J.C. Verhoef, C. Cullander, S.G. Romeijn, J.F. Nagelkerke, F.W.H.M. Merkus, Confocal laser scanning microscopic visualization of the transport of dextrans after nasal administration to rats: Effects of absorption enhancers, Pharm. Res. 14 (1997) 631-637.
82. E. Marttin, J.C. Verhoef, S.G. Romeijn, P. Zwart, F.W.H.M. Merkus, Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vivo., Int. J. Pharm. 141 (1996) 151-160.
83. S.G. Romeijn, J.C. Verhoef, E. Marttin, F.W.H.M. Merkus, The effect of nasal drug formulations on ciliary beating in vitro, Int. J. Pharm. 135 (1996) 137-145.
84. E. Adriaens, J. Voorspoels, J. Mertens, J.P. Remon, Effect of absorption enhancers on ciliated epithelium: A novel in vivo toxicity screening method using rotifers, Pharm. Res. 14 (1997) 541-545.
85. R. Krishnamoorthy, A.M. Wolka, Z. Shao, A.K. Mitra, Cyclodextrins as mucosal absorption promoters IV. Evaluation of nasal mucotoxicity, Eur. J. Pharm. Biopharm. 41 (1995) 296-301.
86. E. Marttin, J.C. Verhoef, S.G. Romeijn, F.W.H.M. Merkus, Effects of absorption enhancers on rat nasal epithelium in vivo. Release of marker compounds in the nasal cavity, Pharm. Res. 12 (1995) 1151-1157.
87. F.W.H.M. Merkus, J.C. Verhoef, S.G. Romeijn, N.G.M. Schipper, Interspecies differences in the nasal absorption of insulin, Pharm. Res. 8 (1991) 1343.
88. A. Adjei, D. Sundberg, J. Miller, A. Chun, Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res. 9 (1992) 244-249.
89. F.W.H.M. Merkus, N.G.M. Schipper, J.C. Verhoef, The influence of absorption enhancers on intranasal insulin absorption in normal and diabetic subjects, J. Control. Rel. 41 (1996) 69-75.
90. N.G.M. Schipper, S.G. Romeijn, J.C. Verhoef, F.W.H.M. Merkus, Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: Powder more effective than liquid formulations, Pharm. Res. 10 (1993) 682-686.
91. H. Nomura, S. Akamisaka, K. Maruyama, Effects of a dosing solution on the nasal absorption of non-glycosylated recombinant human granulocyte colony-stimulating factor in rats, Biol. Pharm. Bull. 19 (1996) 1490-1493.
92. A. De Ascentiis, R. Bettini, G. Caponetti, et al., Delivery of nasal powders of β-cyclodextrin by insufflation, Pharm. Res. 13 (1996) 734-738.
93. F.M. Sakr, Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations, Int. J. Pharm. 132 (1996) 189-194.
94. C. Agerholm, L. Bastholm, P.B. Johansen, M.H. Nielsen, F. Elling, Epithelial transport and bioavailability of intranasally administered human growth hormone formulated with the absorption enhancers didecanoyl-L-α-phosphatidylcholine and α-cyclodextrin in rabbits, J. Pharm. Sci. 83 (1994) 1706-1711.
95. I.J. Gill, A.N. Fisher, M. Hinchcliffe, et al., Cyclodextrins as protection agents against enhancer damage in nasal delivery systems II. Effect on in vivo absorption of insulin and histopathology of nasal membrane, Eur. J. Pharm. Sci. 1 (1994) 237-248.
96. K. Abe, T. Irie, K. Uekama, Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-β-cyclodextrin, Chem. Pharm. Bull. 43 (1995) 2232-2237.
97. A. Martini, R. Artico, P. Civaroli, L. Muggetti, R. De Ponti, Critical micellar concentration shifting as a simple tool for evaluating cyclodextrin/enhancer interactions, Int. J. Pharm. 127 (1996) 239-244.
98. C. Vermehren, H.S. Hansen, M.K. Thomsen, Time dependent effects of two absorption enhancers on the nasal absorption of growth hormone in rabbits, Int. J. Pharm. 128 (1996) 239-250.
99. T. Irie, K. Abe, H. Adachi, et al., Potential use of 2-hydroxypropyl-β-cyclodextrin in designing nasal preparation of insulin involving lipophilic absorption enhancer HPE-101, Drug Deliv. Syst. 7 (1992) 91-95.
100. K. Abe, T. Irie, H. Adachi, K. Uekama, Combined use of 2-hydroxypropyl-β-cyclodextrin and a lipophilic absorption enhancer in nasal delivery of the LHRH agonist, buserelin acetate, in rats, Int. J. Pharm. 123 (1995) 103-112.
101. K. Abe, T. Irie, K. Uekama, Optimal use of absorption enhancer HPE-101 solubilized in hydroxypropyl-β-cyclodextrin for facilitating nasal permeability in rats, Pharm. Sci. 1 (1995) 563-567.
102. T. Irie, K. Abe, T. Ishiguro, K. Uekama, Optimization effects of hydroxypropyl-β-cyclodextrin in combination with nasal absorption enhancer HPE-101, in: V.H.L. Lee (Ed.), Proc. 23rd Int. Symp. Controlled Release Bioact. Mater., The Controlled Release Society, Kyoto, 1996, pp 159-160.
103. H. Okamoto, H. Komatsu, M. Hashida, H. Sezaki, Effects of β-cyclodextrin and di-O-methyl-β-cyclodextrin on the percutaneous absorption of buthylparaben, indomethacin and sulfanilic acid, Int. J. Pharm. 30 (1986) 35-45.
104. K. Uekama, K. Masaki, K. Arimori, T. Irie, F. Hirayama, Effects of β- and dimethyl β-cyclodextrins on release and percutaneous absorption behaviors of prednisolone from some ointment bases, Yakugaku Zasshi 107 (1987) 449-456.
105. K. Uekama, T. Irie, M. Sunada, M. Otagiri, Y. Arimatsu, S. Nomura, Alleviation of prochlorperazine-induced primary irritation of skin by cyclodextrin complexation, Chem. Pharm. Bull. 30 (1982) 3860-3862.
106. U. Vollmer, B.W. Müller, J. Peeters, J. Mesens, B. Wilffert, T. Peters, A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats, J. Pharm. Pharmacol. 46 (1994) 19-22.
107. J.Y. Legendre, I. Rault, A. Petit, et al., Effects of β-cyclodextrins on skin: Implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977, Eur. J. Pharm. Sci. 3 (1995) 311-322.
108. T. Kondo, T. Irie, K. Uekama, Combination effects of αcyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits, Biol. Pharm. Bull. 19 (1996) 280-286.
109. Y. Watanabe, Y. Matsumoto, M. Seki, M. Takase, M. Matsumoto, Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits, Chem. Pharm. Bull. 40 (1992) 3042-3047.
110. K. Uekama, H. Arima, T. Irie, K. Matsubara, T. Kuriki, Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated β-cyclodextrin, J. Pharm. Pharmacol. 41 (1989) 874-876.
111. K. Matsubara, T. Kuriki, H. Arima, K. Wakamatsu, T. Irie, K. Uekama, Possible use of diethyl-β-cyclodextrin in preparation of sustained-release oily injection of buserelin acetate (LHRH agonist), Drug Deliv. Syst. 5 (1990) 95-99.
112. K. Matsubara, T. Irie, K. Uekama, Controlled release of the LHRH agonist buserelin acetate from injectable suspensions containing triacethylated cyclodextrins in an oil vehicle, J. Control. Rel. 31 (1994) 173-180.
113. J. Szejtli, Cyclodextrin Technology. Kluwer, Boston MA, 1998.
114. R. Anand, S. Nayyar, J. Pitha, C.R. Merril, Sulphated sugar alpha-cyclodextrin sulphate, a uniquely potent anti-HIV agent, also exhibits marked synergism with AZT, and lymphoproliferative activity, Antiviral Chem. Chemother. 1 (1990) 41-46.
115. T. Moriya, H. Kurita, K. Matsumoto, et al., Potent inhibitory effect of a series of modified cyclodextrin sulfates (mCDS) on the replication of HIV-1 in vitro, J. Med. Chem. 34 (1991) 2301-2304.
116. D.B. Weiner, W.V. Williams, P.B. Weisz, M.I. Greene, Synthetic cyclodextrin derivatives inhibit HIV infection in vitro, Pathobiol. 60 (1992) 206-212.
117. T. Otake, D. Schols, M. Witvrouw, et al., Modified cyclodextrin sulphates(mCDS11) have potent inhibitory activity against HIV and high oral bioavailability, Antiviral Chem. Chemother. 5 (1994) 155-161.
118. J. Folkman, P.B. Weisz, M.M. Joullié, W.W. Li, W.R. Ewing, Control of angiogenesis with synthetic heparin substitutes, Science 243 (1989) 1490-1493.
119. W.W. Li, R. Casey, E.M. Gonzalez, J. Folkman, Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization, Invest. Ophthalmol. Vis. Sci. 32 (1991) 2898-2905.
120. J. Wong, N. Wang, J.W. Miller, J.S. Schuman, Modulation of human fibroblast activity by selected angiogenesis inhibitors, Exp. Eye Res. 58 (1994) 439-451.
121. K. Shiotani, T. Irie, K. Uekama, Y. Ishimaru, Cyclodextrin sulfates in parenteral use: Protection against gentamicin nephrotoxicity in the rat, Eur. J. Pharm. Sci. 3 (1995) 139-151.
122. T. Kajio, K. Kawahara, K. Kato, Stabilization of basic fibroblast growth factor with dextran sulfate, FEBS Lett. 306 (1992) 243-246.
123. S. Faham, R.E. Hileman, J.R. Fromm, R.J. Linhardt, D.C. Rees, Heparin structure and interactions with basic fibroblast growth factor, Science 271 (1996) 1116-1120.
124. K. Fukunaga, S. Hijikata, K. Ishimura, R. Sonoda, T. Irie, K. Uekama, Aluminium β-cyclodextrin sulphate as a stabilizer and sustained-release carrier for basic fibroblast growth factor, J. Pharm. Pharmacol. 46 (1994) 168-171.
125. K. Fukunaga, K. Ishimura, S. Hijikata, R. Sonoda, T. Irie, K. Uekama, Stabilization and controlled-release of basic fibroblast growth factor by water-insoluble aluminum salts of cyclodextrin sulfates, Drug Deliv. Syst. 9 (1994) 167-172.
126. J. Folkman, S. Szabo, M. Stovroff, P. McNeil, W. Li, Y. Shing, Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing, Ann. Surg. 214 (1991) 414-425.
127. H.C. Herrmann, S.S. Okada, E. Hozakowska, et al., Inhibition of smooth muscle cell proliferation and experimental angioplasty restenosis by β-cyclodextrin tetradecasulfate, Arterioscler. Thromb. 13 (1993) 924-931.
128. S.S. Okada, A. Kuo, M.R. Muttreja, E. Hozakowska, P.B. Weisz, E.S. Barnathan, Inhibition of human vascular smooth muscle cell migration and proliferation by β-cyclodextrin tetradecasulfate, J. Pharmacol. Exp. Ther. 273 (1995) 948-954.
129. W.B. Bachinsky, E.S. Barnathan, H. Liu, et al., Sustained inhibition of intimal thickening: In vitro and in vivo effects of polymeric β-cyclodextrin sulfate, J. Clin. Invest. 96 (1995) 2583-2592.
130. K. Ishimura, K. Fukunaga, T. Ohta, H. Nakamura, T. Irie, K. Uekama, Preparation of β-cyclodextrin sulfate-immobilized hydrophilic vinyl-polymer gel as a selective, high recovery and stable adsorbent for high-performance affinity chromatography of heparin-binding substances, Chromatographia 41 (1995) 349-352.
131. K. Ishimura, K. Fukunaga, T. Irie, K. Uekama, T. Ohta, H. Nakamura, Application of a β-cyclodextrin sulfate-immobilized precolumn to selective on-line enrichment and separation of heparin-binding proteins by column-switching high-performance liquid chromatography, J. Chromatogr. A 769 (1997) 209-214.
132. J. Lisziewicz, D. Sun, M. Klotman, S. Agrawal, P. Zamecnik, G. Robert, Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment, Proc. Natl. Acad. Sci. USA 89 (1992) 11209-11213.
133. R.L. Juliano, S. Akhtar, Liposomes as a drug delivery system for antisense oligonucleotides, Antisense Res. Dev. 2 (1992) 165-176.
134. E.L. Barry, F.A. Gesek, P.A. Friedman, Introduction of antisense oligonucleotides into cells by permeabilization with streptolysin O, Biotechniques 15 (1993) 1016-1018.
135. A.M. Krieg, J. Tonkinson, S. Matson, et al., Modification of antisense phosphodiester oligodeoxynucleotides by 5′ cholesteryl moiety increases cellular association and improves efficacy, Proc. Natl. Acad. Sci. USA 90 (1993) 1048-1052.
136. T. Cserháti, E. Forgács, J. Szejtli, Inclusion complex formation of antisense nucleotides with hydroxypropyl-β-cyclodextrin, Int. J. Pharm. 141 (1996) 1-7.
137. Q. Zhao, J. Temsamani, S. Agrawal, Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery, Antisense Res. Dev. 5 (1995) 185-192.
138. Q. Zhao, J. Temsamani, P.L. Tadarola, S. Agrawal, Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs, Biochem. Pharmacol. 52 (1996) 1537-1544.
139. S. Abdou, J. Collomb, F. Sallas, A. Marsura, C. Finance, Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence, Arch. Virol. 142 (1997) 1585-1602.
140. M.A. Croyle, B.J. Roessler, G.L. Amidon, Beta cyclodextrins enhance gene delivery to the intestine in: K.-E. Falk, T. Okano (Eds.), Proc. 24th Int. Symp. Controlled Release Bioact. Mater., The Controlled Release Society, Stockholm, 1997, pp 675-676.
141. I. Habus, Q. Zhao, S. Agrawal, Synthesis, Hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide-amino-β-cyclodextrins and adamantane conjugates, Bioconjugate Chem. 6 (1995) 327-331.
142. T. Morii, J. Yamane, Y. Aizawa, K. Makino, Y. Sugiura, Cooperative oligomerization enhances sequence-selective DNA binding by a short peptide, J. Am. Chem. Soc. 118 (1996) 10011-10017.
143. J. Szejtli, Cyclodextrins in diagnosis, Kontakte (Darmstadt) 1 (1988) 31-36.
144. A. Sharma, L.S. Janis, Lipoprotein-cyclodextrin interaction, Clin. Chim. Acta 199 (1991) 129-138.
145. 2+, J. Biol. Chem. 254 (1979) 9621-9626.
146. H. Sugiuchi, Y. Uji, H. Okabe, T. Irie, K. Uekama, Differential effects of modified cyclodextrins on serum lipoprotein fractions. Application to direct measurement of high-density lipoprotein in human serum, in: T. Osa, et al. (Eds.), Proc. 7th Int. Cyclodextrins Symp., Komiyama, Tokyo, 1994, pp. 532-535.
147. H. Sugiuchi, Y. Uji, H. Okabe, et al., Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated α-cyclodextrin, Clin. Chem. 41 (1995) 717-723.
148. N. Harris, V. Galpchian, N. Rifai, Three routine methods for measuring high-density lipoprotein cholesterol compared with the reference method, Clin. Chem. 42 (1996) 738-743.
149. M. Nauck, W. März, J. Jarausch, et al., Multicenter evaluation of a homogenous assay for HDL-cholesterol without sample pretreatment, Clin. Chem. 43 (1997) 1622-1629.
150. M. Okazaki, K. Sasamoto, T. Muramatsu, S. Hosaki, Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC, Clin. Chem. 43 (1997) 1885-1890.
151. H. Sugiuchi, T. Irie, Y. Uji, et al., Homogenous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and α-cyclodextrin sulfate, Clin. Chem. 44 (1998) 522-531.